Canine non-B, non-T NK lymphocytes have a potential antibody-dependent cellular cytotoxicity function against antibody-coated tumor cells

BMC Vet Res. 2019 Oct 14;15(1):339. doi: 10.1186/s12917-019-2068-5.

Abstract

Background: The antibody-dependent cellular cytotoxicity (ADCC) is a cell-mediated immune defense mechanism in which effector immune cells actively lyse antibody-coated target cells. The ADCC of tumor cells is employed in the treatment of various cancers overexpressing unique antigens, and only natural killer (NK) cells are known to be major effectors of antibody mediated ADCC activity. Canine NK cells are still defined as non-B, non-T large granular lymphocytes because of the lack of information regarding the NK cell-restricted specific marker in dogs, and it has never been demonstrated that canine NK cells have ADCC ability against tumor cells. In the present study, we investigated whether canine non-B, non-T NK cells have ADCC ability against target antibody-coated tumor cells, using cetuximab and trastuzumab, the only human antibodies reported binding to canine cancer cells.

Results: Activated canine non-B, non-T NK cells (CD3-CD21-CD5-TCRαβ-TCRγδ-) for 13~17 days ex vivo showed ADCC ability against trastuzumab- or cetuximab-coated target tumor cells expressing various levels of human epidermal growth factor receptor 2 (HER-2) and epidermal growth factor receptor (EGFR). Trastuzumab and cetuximab induced significant ADCC responses of canine NK cells even in CMT-U334 and CF41.Mg cells expressing low levels of HER-2 and/or EGFR, as well as in SKBR3 and DU145 cells overexpressing HER-2 and/or EGFR. The trastuzumab-mediated ADCC activity of NK cells was significantly enhanced by treatment with rcIL-21.

Conclusions: The results of this study suggest that canine non-B, non-T NK lymphocytes have a potential ADCC function and that combinational strategies of monoclonal antibodies with either cytokines, which activate NK cells in vivo, or adoptive transfer of NK cells may be a feasible method for amplifying the efficacy of immunotherapy against malignant cancers even with very low expression of target molecules in dogs.

Keywords: Antibody-dependent cellular cytotoxicity; Canine; Cetuximab; Natural killer cells; Trastuzumab.

MeSH terms

  • Animals
  • Antibodies, Monoclonal / immunology
  • Antibody-Dependent Cell Cytotoxicity*
  • Antineoplastic Agents, Immunological / pharmacology
  • Cell Line, Tumor
  • Cetuximab / pharmacology
  • Dogs
  • ErbB Receptors / antagonists & inhibitors
  • Humans
  • Killer Cells, Natural / immunology*
  • Neoplasms / drug therapy*
  • Receptor, ErbB-2 / antagonists & inhibitors
  • Trastuzumab / pharmacology

Substances

  • Antibodies, Monoclonal
  • Antineoplastic Agents, Immunological
  • EGFR protein, human
  • ERBB2 protein, human
  • ErbB Receptors
  • Receptor, ErbB-2
  • Trastuzumab
  • Cetuximab